Jung H, Roh H K
Department of Obstetrics and Gynecology, College of Medicine, Chosun University, Kwangju, Korea.
J Assist Reprod Genet. 2000 Jan;17(1):28-33. doi: 10.1023/a:1009445913156.
Our purpose was to determine if pregnancy rates (PRs) for hMG (human menopausal gonadotropin)-stimulated IVF-ET (in vitro fertilization--embryo transfer) can be increased by estradiol (E2) supplementation from the early proliferative phase to the late secretory phase of the endometrium.
Eighty-one infertile women with pure tubal factor were randomized into two groups. One group received no E2 supplementation (control group) and the other received oral E2 supplementation (2 mg two times daily) from the early proliferative phase starting on the third day of the menstrual cycle to the late secretory phase of the endometrium, with hMG stimulation for ovulation induction starting on the sixth day of the menstrual cycle.
In 85 cycles, at least one embryo was transferred. Compared with the control group (n = 27 cycles), the E2 supplementation group (n = 58 cycles) had a significantly higher PR (control, 25.9%, versus E2 supplementation, 48.3%) and IR per ET (control, 10%, versus E2 supplementation, 26%), but FRs per retrieved oocytes were not statistically different between the two groups (control, 74%, versus E2 supplementation group, 73%). Four spontaneous abortions occurred in the E2 supplementation group, and one case in the control group. Ectopic pregnancy occurred in one case in the control group.
Clinical PRs and IRs in the E2 supplementation group were significantly higher than in the control group, while FRs in the control group did not differ statistically from the E2 supplementation group. This suggests that E2 supplementation from the early proliferative phase to the late secretory phase of the endometrium in hMG-stimulated IVF-ET increases the receptivity of the endometrium for transferred embryos and clinical PRs.
我们的目的是确定在人绝经期促性腺激素（hMG）刺激的体外受精 - 胚胎移植（IVF - ET）中，从子宫内膜增殖早期到分泌晚期补充雌二醇（E2）是否能提高妊娠率（PR）。
81例单纯输卵管因素不孕的女性被随机分为两组。一组不补充E2（对照组），另一组从月经周期第3天开始的增殖早期至子宫内膜分泌晚期口服E2补充剂（每日2次，每次2mg），月经周期第6天开始用hMG刺激诱导排卵。
在85个周期中，至少移植了一个胚胎。与对照组（n = 27个周期）相比，E2补充组（n = 58个周期）的PR显著更高（对照组为25.9%，E2补充组为48.3%），每次胚胎移植的着床率（IR）也更高（对照组为10%，E2补充组为26%），但两组每个获卵的受精率（FR）无统计学差异（对照组为74%，E2补充组为73%）。E2补充组发生4例自然流产，对照组发生1例。对照组发生1例异位妊娠。
E2补充组的临床PR和IR显著高于对照组，而对照组的FR与E2补充组无统计学差异。这表明在hMG刺激的IVF - ET中，从子宫内膜增殖早期到分泌晚期补充E2可提高子宫内膜对移植胚胎的接受性和临床PR。
